Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)

• ClinicalTrials.gov Identifier: NCT00065299
• Recruitment Status: Completed
• First Posted: July 22, 2003
• Last Update Posted: June 24, 2005
• Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Information provided by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Study Description

Brief Summary:

Phenylketonuria (PKU) is a rare genetic condition. If not treated, PKU can cause severe mental retardation. Women with PKU are advised to eat a special diet when pregnant to prevent mental retardation in their children. This study will evaluate the effects of that diet on the children of mothers with PKU.

Condition or disease	Intervention/treatment	Phase
Phenylketonuria	Behavioral: Restricted phenylalanine diet	Not Applicable

Detailed Description:

PKU is an autosomal recessive trait caused by the absence of phenylalanine hydroxylase. Phenylalanine hydroxylase is an enzyme involved in the metabolism of phenylalanine (Phe). When phenylalanine hydroxylase is absent or defective, Phe levels rise and toxic Phe metabolites accumulate, causing central nervous system injury. PKU is a treatable disease. Affected individuals must adhere to a diet low in Phe during childhood. Women with PKU should also adhere to a low Phe diet before and during pregnancy to avoid fetal damage. The offspring of women with untreated maternal hyperphenylalaninemia (HPA) usually exhibit mental retardation, microcephaly, growth retardation, and other congenital anomalies. This study will examine the effect of a restricted Phe diet on reproductive outcome in women with maternal HPA.

Participants in this study will be women with HPA whose blood Phe values are persistently greater than 4 mg/dl. Those women with blood Phe values consistently greater than 8 mg/dl will be placed on a Phe restricted diet to maintain plasma Phe concentrations between 2 and 8 mg/dl. This level of control is practical and achievable. Due to a gradient of increasing Phe level from mother to fetus, levels in the latter would vary from 3.5 to 12 mg/dl; these levels are usually associated with normal outcomes. Women will be monitored throughout their pregnancy on obstetric, biochemical, and nutritional parameters. Women on the Phe restricted diet will be given enough Phe-limited protein, calories, vitamins, and minerals to maintain adequate nutritional status. Folate supplementation will be provided. If indicated clinically, tyrosine (Tyr) and supplemental trace metals will be prescribed.

A matching control sample of women and their offspring will be developed in collaboration with associated coordinating and collaborating centers. The offspring of both groups of mothers will be followed as long as the project permits. Those offspring born to mothers admitted to the project during the first 2 to 3 years of the study will be assessed on their intellectual ability and physical health, as well as academic achievement in school. Those admitted during the last 3 to 4 years of the study will be assessed on their intellectual ability and physical health, recognizing that limited data will be available for these offspring.

Study Design

• Study Type: Interventional (Clinical Trial)
• Enrollment: 572 participants
• Allocation: Non-Randomized
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Effects of Maternal Phenylketonuria (PKU) on Pregnancy Outcome
• Study Start Date: May 1984
• Study Completion Date: April 2000

Arms and Interventions

Outcome Measures

Eligibility Criteria

• Ages Eligible for Study: 0 Years and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria

• Live in community setting
• Become pregnant or give birth during the term of the investigation
• Identified early in pregnancy
• Dietary therapy instituted prior to conception whenever possible
• Diagnosis of PKU based on results of Phe challenge, or clear diagnostic evidence in medical record
• Blood Phe > 4 mg/dl
• Intellectually able to understand and comply with the requirements of the Phe restricted diet, understand an informed consent, and adequately communicate with clinic personnel
• IQ > 70

Inclusion Criteria for Controls

• Heterozygous sisters to HPA women
• Matched control from maternity facility; pregnancy and offspring from a non-PKU female and a PKU male

Exclusion Criteria

• Women with evidence of pterin defect

Contacts and Locations

Locations

United States, California

University of Southern California School of Medicine

Los Angeles, California, United States, 90027

United States, Illinois

University of Illinois at Chicago

Chicago, Illinois, United States

United States, Texas

University of Texas Medical Branch at Galveston

Galveston, Texas, United States

Sponsors and Collaborators

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Investigators

• Principal Investigator: Richard Koch, M.D.; University of Southern California
• Principal Investigator: Reuben Matalon, M.D.; University of Illinois at Chicago
• Principal Investigator: Bobbye M. Rouse, M.D.; University of Texas at Galveston

More Information

Publications:

Levy HL, Guldberg P, Guttler F, Hanley WB, Matalon R, Rouse BM, Trefz F, Azen C, Allred EN, de la Cruz F, Koch R. Congenital heart disease in maternal phenylketonuria: report from the Maternal PKU Collaborative Study. Pediatr Res. 2001 May;49(5):636-42. doi: 10.1203/00006450-200105000-00005.

Koch R, Levy HL, Matalon R, Rouse B, Hanley WB, Trefz F, Azen C, Friedman EG, de la Cruz F, Guttler F, et al. The international collaborative study of maternal phenylketonuria: status report 1994. Acta Paediatr Suppl. 1994 Dec;407:111-9. doi: 10.1111/j.1651-2227.1994.tb13468.x.

Matalon R, Michals K, Azen C, Friedman E, Koch R, Rouse B, Hanley WB, de la Cruz F. Maternal PKU Collaborative Study: pregnancy outcome and postnatal head growth. J Inherit Metab Dis. 1994;17(3):353-5. doi: 10.1007/BF00711828. No abstract available.

Koch R, Levy HL, Matalon R, Rouse B, Hanley W, Azen C. The North American Collaborative Study of Maternal Phenylketonuria. Status report 1993. Am J Dis Child. 1993 Nov;147(11):1224-30. doi: 10.1001/archpedi.1993.02160350098015.

Koch R, Hanley W, Levy H, Matalon R, Rouse B, Dela Cruz F, Azen C, Gross Friedman E. A preliminary report of the collaborative study of maternal phenylketonuria in the United States and Canada. J Inherit Metab Dis. 1990;13(4):641-50. doi: 10.1007/BF01799519.

• ClinicalTrials.gov Identifier: NCT00065299
• Other Study ID Numbers: NICHD-PKU; 1N01HD23148; 1N01HD23155; 1N01HD23156
• First Posted: July 22, 2003
• Last Update Posted: June 24, 2005
• Last Verified: May 2000

Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):

Hyperphenylalaninemia; PKU; Maternal PKU; Pregnancy outcome; Phenylalanine restricted diet; Tyrosine supplementation; Maternal hyperphenylalanemia during pregnancy

Additional relevant MeSH terms:

Phenylketonurias; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Amino Acid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Metabolic Diseases